COMMUNIQUÉS West-GlobeNewswire

Zealand Pharma A/S exercises its authorization granted by its extraordinary general meeting held on July 31, 2017
09/08/2017
Company announcement - No. 30/2017 Zealand Pharma A/S exercises its authorization granted by its extraordinary general meeting held on July 31, 2017 in connection with its initial public offering of American Depositary [...]
Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update
08/08/2017
Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 2017; quarter-end cash and restricted cash position of $475.8 million, provides [...]
Novavax Reports Second Quarter 2017 Financial Results
08/08/2017
GAITHERSBURG, Md., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2017. Second Quarter and Subsequent [...]
Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
08/08/2017
Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus ® Paris, France - August 8, 2017 - Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. ("Merck") on [...]
Sanofi intente une action en justice aux Etats-Unis pour défendre les brevets de Lantus®
08/08/2017
Sanofi intente une action en justice aux Etats-Unis pour défendre les brevets de Lantus ® Paris, France - Le 8 août 2017 - Sanofi annonce aujourd'hui avoir intenté le 8 août 2017 une action en contrefaçon contre Merck [...]
Ossur Hf : Transactions in relation to share buyback program
08/08/2017
A nnouncement from Össur hf. No. 55/2017 Reykjavík, 8 August 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is [...]
Novo Nordisk A/S - Share repurchase programme
08/08/2017
Bagsværd, Denmark, 8 August 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]
iTeos Therapeutics SA: iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
08/08/2017
iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference Gosselies, Belgium - August 8, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
08/08/2017
FIT Biotech Oy Company release August 8, 2017 at 02:00 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress
08/08/2017
~ Advancing Gene Therapy Programs in Hemophilia B and Huntington's Disease ~ ~ Provides Update on Research Collaboration with Bristol-Myers Squibb ~ ~ Makes New Appointments to Company Leadership and Nominations to [...]
Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update
08/08/2017
Completed US IPO Continues to advance lead candidate RPL554 with four clinical trials commenced LONDON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a [...]
Communiqué de presse relatif à la solution ophtalmique de latanoprostène bunod, 0,024%
08/08/2017
Communiqué de presse Communiqué de presse relatif à la solution ophtalmique de latanoprostène bunod, 0,024% 8 août 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société [...]
Press Release concerning latanoprostene bunod ophthalmic solution, 0.024%
08/08/2017
Press Release Press Release concerning latanoprostene bunod ophthalmic solution, 0.024% 8 August 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company [...]
argenx to Present at Wedbush PacGrow Healthcare Conference
08/08/2017
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe [...]
MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
08/08/2017
COMPANY ANNOUNCEMENT / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 8, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced it has signed a health care services [...]
MDxHealth annonce un contrat de service avec Kaiser Southern California Permanente Medical Group
08/08/2017
Annonce d'entreprise / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CALIFORNIE et HERSTAL, BELGIQUE - 07:00 CEST, le 8 août, 2017 - MDxHealth SA (Euronext: MDXH.BR) a annoncé aujourd'hui la signature d'un [...]
INNATE PHARMA : Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 4 aout 2017
08/08/2017
nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 4 août 2017 Marseille, le 8 août 2017, 7h00 CEST Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l'Autorité [...]
INNATE PHARMA : Number of shares and voting rights of Innate Pharma as at August 4, 2017
08/08/2017
NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT AUGUST 4, 2017 Marseille, France, AUGUST 8, 2017, 7:00 AM CEST Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of [...]
VIFOR PHARMA REPORTS STRONG H1 2017 RESULTS AND RAISES GUIDANCE
08/08/2017
PRESSEMITTEILUNG PRESS RELEASE COMMUNIQUÉ DE PRESSE This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that [...]

Pages